FAP and cancer: Despite substantial evidence supporting the effective suppression of FAPα-mediated signaling, it is also important to consider potential consequences: inhibition of the PI3K/Akt signaling pathway activated by FAPα can trigger compensatory activation of the RAS/RAF/MEK/ERK cascade, as demonstrated in various cancers, and thus targeting FAPα may similarly induce alternative proliferative signaling, reducing overall therapeutic efficacy [91].